Tanashyan M M, Lagoda O V, Antonova K V
Research Centre of Neurology, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(9):70-75. doi: 10.17116/jnevro20151159170-75.
Metabolic syndrome is a serious risk factor for acute and chronic cerebrovascular disease, which are a leading cause of disabling conditions. The association of proatherogenic effects of the main components of metabolic syndrome--hyperinsulinemia, arterial hypertension, dyslipidemia and obesity--leads to prominent haemorheological and hemostasis changes, which in turn play a pivotal role in the initiation, course and outcome of cerebrovascular pathology. Metabolic syndrome also influences the efficacy of the main pathogenetic therapy of cerebrovascular diseases--antithrombotic therapy. Thus, primary and secondary prevention of cerebrovascular disease in patients with metabolic syndrome should include haemangiocorrective, antithrombotic, antioxidant and endothelium-protective treatment, as well as therapy of the main components of metabolic syndrome.
代谢综合征是急慢性脑血管疾病的严重危险因素，而急慢性脑血管疾病是导致残疾的主要原因。代谢综合征的主要成分——高胰岛素血症、动脉高血压、血脂异常和肥胖——的促动脉粥样硬化作用相互关联，导致显著的血液流变学和止血变化，进而在脑血管病变的发生、发展过程和转归中起关键作用。代谢综合征还影响脑血管疾病主要病因治疗——抗血栓治疗的疗效。因此，代谢综合征患者脑血管疾病的一级和二级预防应包括血管纠正、抗血栓、抗氧化和内皮保护治疗，以及代谢综合征主要成分的治疗。
